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Abstract
Introduction: West Nile virus (WNV) immunoglobulin M (IgM) antibodies have been shown to persist for up to 500 days in 
certain patients. To evaluate the usefulness of immunoglobulin G (IgG) avidity assessment in the diagnosis of WNV infection, we 
analyzed 54 WNV IgM- and/or IgG-positive serum samples from 39 patients with neuroinvasive disease and 15 asymptomatic 
cases tested during a seroprevalence investigation. Methods: Serological tests (WNV IgM/IgG antibody detection, IgG avidity) 
were performed using commercially available enzyme-linked immunosorbent assays. Results: WNV IgM antibodies were 
detected in 47 (87%) samples. Acute/recent WNV infection was confirmed based on low/borderline avidity index (AI) in 44 
IgM-positive samples (93.6%). In three IgM-positive samples (6.4%), high IgG AIs were detected, thus indicating persisting 
IgM antibodies from previous infections. All IgM-negative samples showed high AIs. Patients with WNV neuroinvasive disease 
tested within 30 days showed low AIs. In six patients tested 34-50 days after disease onset, AI was borderline (42%-60%), 
suggesting earlier WNV IgG maturation. Samples with the highest IgM values were associated with the lowest AIs (Spearman's 
rho coefficient -0.767, p < 0.001). Conclusions: Our results indicate that IgG avidity differentiates current/recent WNV infection 
from persistent IgM seropositivity from the previous WNV transmission season both in patients with WNV neuroinvasive disease 
and in asymptomatic persons. A strong negative correlation between IgM antibody levels and AI indicates that in cases with very 
high IgM levels, determination of IgG avidity may not be necessary. As many patients showed rapid avidity maturation, low IgG 
avidity is indicative of WNV infection within the previous month.
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INTRODUCTION 
West Nile virus (WNV) is a mosquito-borne virus that 
belongs to the genus Flavivirus of the family Flaviviridae. Most 
human infections (approximately 80%) caused by this virus are 
subclinical. Approximately 20% of infected persons develop 
nonspecific febrile disease (WNV fever)1. Neuroinvasive 
disease (meningitis, encephalitis, and acute flaccid paralysis) 
occurs in less than 1% of infected persons but carries a fatality 
rate of approximately 10%2. Although the onset of symptoms 
is preceded by a viremic period, viremia persists for only a 
short period and the disease usually manifests after the virus 
is no longer detectable. Therefore, the diagnosis of WNV 
infection is usually based on serological methods. Usually, 
immunoglobulin M (IgM) is considered to be a marker of 
acute infection3. However, IgM antibodies for WNV have 
been shown to persist for up to 500 days or even longer in 
certain patients4. As WNV IgM antibodies may last from one 
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TABLE 1: IgG avidity in patients with West Nile virus neuroinvasive disease and asymptomatic persons.
IgM ELISA result Tested (%) Low AI (%) Borderline AI (%) High AI (%)
All participants (n=54)
IgM-positive/equivocal 47 (87.0) 36 (76.6) 8 (17.0) 3 (6.4)
IgM-negative 7 (13.0) 0 (0.0) 0 (0.0) 7 (100.0)
WNV neuroinvasive disease (n=39)
IgM-positive/equivocal 39 (100.0) 33 (84.6) 6 (15.4) 0 (0.0)
IgM-negative 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Asymptomatic persons (n=15)
IgM-positive/equivocal 8 (53.3) 3 (37.5) 2 (25.0) 3 (37.5)
IgM-negative 7 (46.7) 0 (0.0) 0 (0.0) 7 (100.0)
IgM: immunoglobulin M; ELISA: enzyme-linked immunosorbent assay; AI: avidity index; WNV: West Nile virus.
transmission season to the next, an early-season reactive IgM 
test could result from either a recent or a past WNV infection5. 
In addition, WNV immunoglobulin A (IgA) antibodies show a 
persistence pattern similar to that of IgM antibodies, and are 
not helpful in the diagnosis of recent WNV infections. Two 
studies conducted among viremic blood donors showed that IgA 
antibodies were remarkably persistent, particularly during the 
first 200 days after infection, and in 57% of cases, they persisted 
for more than a year6,7. Avidity testing for the differentiation 
of recent and past antibody response has been used for the 
serodiagnosis of several flaviviruses such as dengue and tick-
borne encephalitis virus8-10. This test is based on the affinity 
maturation of immunoglobulin G (IgG) antibodies against 
antigens during the immune response. In the primary infection, 
the early IgG antibody response is of a relatively low specificity, 
resulting in low IgG avidity. As the immune response matures, 
IgG antibodies become more specific and IgG avidity continues 
to increase for several months after infection5. 
The aim of this study was to evaluate the usefulness of IgG 
avidity determination in the diagnosis of WNV neuroinvasive 
disease and asymptomatic WNV infection.
METHODS
During five transmission seasons (July 2012-October 2017), 
a total of 54 IgM- and/or IgG-positive serum samples from 
Croatian patients and asymptomatic persons with confirmed 
WNV infection, according to the European Union criteria 
for WNV11, were tested for IgG avidity. Thirty-nine samples 
were obtained from patients with clinical symptoms of WNV 
neuroinvasive disease (meningitis, encephalitis, and/or acute 
flaccid paralysis), collected from 6 to 50 days after the onset 
of symptoms12,13. Fifteen positive samples were identified 
among randomly selected asymptomatic persons during a 
seroprevalence investigation (unpublished data of the Reference 
Centre for Diagnosis and Surveillance of Viral Zoonoses of the 
Croatian Ministry of Health). Serological tests were performed 
at the National Reference Laboratory for Arboviruses, Croatian 
Institute of Public Health. IgM and IgG antibody levels were 
determined using a commercially available enzyme-linked 
immunosorbent assay kit [anti-West Nile virus enzyme-linked 
immunosorbent assay (ELISA) IgM/IgG, Euroimmun, Lübeck, 
Germany] and interpreted according to the manufacturer’s 
instructions: IgM (ratio) < 0.8, negative; 0.8-1.1, borderline; 
>1.1, positive; and IgG (relative units; RU/mL) < 16, negative; 
16-22, borderline; > 22, positive. IgG avidity was tested using 
urea as a denaturing agent (Avidity: West Nile virus ELISA IgG, 
Euroimmun, Lübeck, Germany). The avidity index (AI) was 
calculated and interpreted as follows: < 40%, low; 40%-60%, 
borderline; and > 60%, high.
In all cases, WNV infection was confirmed via a virus 
neutralization test (VNT) performed at the OIE Reference 
Centre for West Nile Disease, Istituto Zooprofilattico 
Sperimentale "G. Caporale", Teramo, Italy14, or via reverse 
transcription polymerase chain reaction (RT-PCR) according 
to the protocol described by Tang et al15.
Statistical analysis
The strength and direction of a possible linear relationship 
between WNV IgM and AI were assessed using Spearman's 
correlation test. For statistical analysis, the software package 
Stata/IC version 11.2 (StataCorp LP, USA) was used.
Ethicals considerations
This study was approved by the Ethics Committee of the 
Croatian Institute of Public Health.
RESULTS
The samples were divided into two groups according to the 
WNV IgM/IgG results: group I (IgM-positive/equivocal and IgG-
positive), 47 (87%) samples; and group II (IgM-negative and IgG-
positive), 7 (13%) samples. In the IgM-positive sample group, 
acute/recent primary WNV infection was confirmed based on IgG 
avidity in 44 (93.6%) patients: low AI was detected in 36 (76.6%) 
patients and borderline AI in 8 (17%) patients. Three (6.4%) IgM-
positive samples, as well as all 7 IgM-negative samples showed 
high AI, indicating a past WNV infection (Table 1). 
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FIGURE 1: IgG avidity in patients with West Nile virus neuroinvasive disease. IgG: immunoglobulin G.
FIGURE 2: Correlation of West Nile virus IgM antibody levels and IgG 
avidity. IgM: immunoglobulin M; IgG: immunoglobulin G.
With regard to clinical symptoms, positive/equivocal IgM 
antibody levels were detected in 39 (100%) patients with WNV 
neuroinvasive disease and in 8 (53.3%) asymptomatic subjects. 
Using AI, acute/recent infection was confi rmed in all IgM-
positive patients (low AI, 33 (84.6%) patients; borderline AI, 6 
(15.4%) patients) and in 5 (62.5%) asymptomatic subjects (low 
AI, 3 (37.5%) patients; borderline AI, 2 (25.0%) patients). Three 
(37.5%) IgM-positive and all 7 IgM-negative asymptomatic 
subjects showed high AIs (Table 1). 
The AIs of WNV IgM-/IgG-positive patients are presented 
in Figure 1. Within 30 days after the disease onset, all patients 
showed low AIs. Six patients tested on days 34, 38, 42, and 50 
showed borderline AIs (42-60%).
There was a statistically significant strong negative 
correlation between IgM antibody levels and AIs. Samples 
with the highest IgM levels were associated with the lowest 
AIs (Spearman's rho coeffi cient -0.767, p<0.001, Figure 2).
DISCUSSION
Owing to the short and low-level viremic period, serology 
remains an important tool for the diagnosis of human WNV 
infection. The detection of IgM antibodies is the most 
commonly used diagnostic method for confi rming a current/
recent infection16. A recently published study from Greece 
showed IgM persistence in 12% of patients 3 years after WNV 
infection17. In addition, a study from Houston  found that 
42%, 34%, and 23% of persons showed positive or equivocal 
results when tested for WNV IgM antibodies approximately 
1, 6, and 8 years post infection, respectively18. The presence 
of WNV-reactive IgM antibodies in the serum, therefore, is 
not necessarily diagnostic of an acute WNV infection5. In this 
study, 87% of tested participants showed positive IgM antibody 
detection tests. By combining IgM levels with IgG avidity 
determination, a recent WNV infection was confi rmed based 
on low/borderline AI in 93.6% of IgM-positive participants. 
However, 6.4% of participants showed high-avidity IgG 
antibodies, indicating that IgM antibodies were refl ective of 
a previous infection. 
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Because the majority of WNV infections are asymptomatic, 
seroprevalence studies performed during/following the 
transmission season provide useful information on virus 
circulation in a particular area. In this study, WNV IgM 
antibodies were detected in 53.3% of asymptomatic persons. In 
62.5% of them, serological response was suggestive of a WNV 
infection contracted during the current transmission season 
(low/borderline AI), whereas 37.5% demonstrated a high AI, 
which indicates persistent IgM antibodies from the previous 
transmission season. All IgM-negative asymptomatic persons 
showed IgG antibodies of high avidity.
During viral infections, maturation of IgG antibodies 
to a high avidity level usually occurs 3 to 6 months after 
infection3. Levett et al.19 found high IgG avidity in all serum 
samples tested six months or more after exposure to WNV, 
indicating that persons exposed to WNV during the preceding 
transmission season will mostly demonstrate high IgG avidity 
if tested the following spring. Low-avidity IgG antibodies 
were identified in 86% of the ELISA tests and 95% of indirect 
immunofluorescence analyses (IFA) of IgG-positive patient 
samples collected between 2 and 43 days after the onset of 
symptoms. In this study, all patients with WNV neuroinvasive 
disease tested within 30 days after the disease onset showed 
low AIs, whereas patients tested 34 to 50 days after disease 
onset showed borderline AIs (42-60%). Prince et al.8 showed 
similar results with regard to dengue virus (DENV) infection. 
When considering IgG avidity, 95% of serum samples collected 
within 30 days after the disease onset were correctly classified 
as primary DENV infections. Fox et al.20 demonstrated even 
earlier maturation of IgG avidity during a WNV infection. The 
AI was low in WNV-positive blood donors tested within 20 days 
of index sampling [WNV ribonucleic acid (RNA)-positive], 
and was borderline in the period between approximately 30 
and 60 days. Surprisingly, 33% of samples collected within 
90 days exhibited high AIs. Particularly noteworthy was a 
cluster of samples with high AIs collected within 25 days from 
index sampling. In addition to rapid maturation of WNV IgG 
antibodies, another possibility is that these individuals were 
exposed to (or vaccinated against) another flavivirus in the past 
and produced high-avidity WNV IgG antibodies as part of an 
anamnestic response to common flavivirus antigens21. 
The results of this study showed a strong negative correlation 
between IgM antibody levels and IgG avidity. Samples with 
the highest WNV IgM levels showed the lowest AI values, 
suggesting that in cases with very high IgM levels, the 
determination of IgG avidity may not be necessary.
In conclusions, our results indicate that IgG avidity 
differentiates current/recent WNV infection from persistent 
IgM seropositivity due to the previous WNV transmission 
season both in patients with WNV neuroinvasive disease and 
in asymptomatic persons. Differentiation of recent infection 
in patients with clinical symptoms of neuroinvasive disease is 
important, as WNV infection could be misdiagnosed for other 
viral central nervous system (CNS) infections with similar 
seasonal distribution (enteroviruses), as well as viruses that may 
present similar clinical symptoms but require specific therapy 
(herpes simplex virus, varicella-zoster virus). In addition, 
detection of a recent WNV infection in asymptomatic patients 
during the transmission season suggests virus circulation in the 
current year. High IgM antibody titer is a strong predictor for 
low IgG avidity. As many patients showed rapid WNV avidity 
maturation, a low AI is indicative of WNV infection within the 
previous month. However, because of the small sample size, 
further studies on a larger cohort are required to confirm this 
observation.
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